PubMed Health⌕ Search

PubMed · 16670670

["Therapeutic" pleural surgery].

Abstract

Renewed interest in carcinological pleura surgery for the treatment of mesothelioma has resulted from an increased incidence of the tumor and also better control of postoperative mortality for an operation with a dramatic reputation. Techniques include pleurectomy, pleurodecrotication and wide pleuropneumectomy. To achive isolated resection of the parietal pleura or a combined resection of the parietal and visceral pleura with more or less wide resection of the diaphragm and pericardium. Indications depend on the tumor extension and the patient's status. Mortality, particularly for wide pleuropneumectomy is no well controlled by well-trained teams and is to the order of 5%. The rate of local recurrence is to the order of 10% and can warrant use of local treatments such as intrathoracic hyperthermic chemotherapy. Median survival for operated mesothelioma is 19 months with a 46% five-year survival for the tumors with the best prognosis. At the present time, radical surgical resection is the basis of local treatment for pleural mesothelioma.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Vénissac, J Mouroux. 2006. ["Therapeutic" pleural surgery].. https://doi.org/10.1016/s0761-8417(06)75430-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Safe fertility-preserving management in gynecological malignancies.

OBJECTIVE: To provide a review in the available literature about the safe fertility-preserving management in gynecological malignancies, focusing on the selection criteria of the patients, treatment options and follow-up. DESIGN: Literature survey. RESULTS: The incidence of cancer in women who still want to get pregnant is increasing significantly. An early detection in gynecological malignancies allows less aggressive approaches to cure such disorders. A more conservative management, which preserves fertility, is considered safe and an option for those who have not completed their child-bearing. CONCLUSIONS: Selected patients with cervical, endometrial and ovarian cancer may be candidates to a safe fertility-preserving management. A careful stage and follow-up of the patients is essential to achieve success with this practice.

Chemotherapy, Adjuvant↗

Defining optimal therapy for muscle invasive bladder cancer.

PURPOSE: We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy. MATERIALS AND METHODS: We reviewed published reports from 1985 to 2006 dealing with the treatment of muscle invasive (stage T2-T4a) bladder cancer. We analyzed all cohort, phase II and randomized phase III studies providing level 1 to 3 evidence impacting survival. RESULTS: Cisplatin based chemotherapy combined with high quality radical cystectomy and complete pelvic lymph node dissection improves survival over that of cystectomy alone. Surgery quality is an important predictor of survival even in patients receiving chemotherapy. Neoadjuvant chemotherapy is favored over adjuvant chemotherapy because it is better tolerated and more patients are able to receive effective therapy before rather than after surgery. CONCLUSIONS: Neoadjuvant chemotherapy followed by radical cystectomy and complete pelvic lymph node dissection is the optimal curative strategy in most patients presenting with muscle invasive bladder cancer.

Chemotherapy, Adjuvant↗